

# 8<sup>th</sup> INTERNATIONAL FORUM ON MOOD AND ANXIETY DISORDERS

*VIENNA, 12-14 NOVEMBER, 2008*



Website: [www.aim-internationalgroup.com/2008/ifmad](http://www.aim-internationalgroup.com/2008/ifmad)



**Final Programme**



## SCIENTIFIC COMMITTEE

### Chairman

Siegfried Kasper (*Austria*)

### Co-Chairman

Stuart A. Montgomery (*United Kingdom*)

### Scientific Advisers

Christer Allgulander (*Sweden*), A. Carlo Altamura (*Italy*), David Baldwin (*United Kingdom*),  
Graham Burrows (*Australia*), Giovanni B. Cassano (*Italy*), Koen Demyttenaere (*Belgium*)  
J.A. den Boer (*The Netherlands*), T. Dinan (*Ireland*), Elias Eriksson (*Sweden*),  
Naomi Fineberg (*United Kingdom*), Teruhiko Higuchi (*Japan*), Robert M.A. Hirschfeld (*USA*),  
Sidney H. Kennedy (*Canada*), Jean-Pierre Lépine (*France*), Mario Maj (*Italy*),  
Alexander A. Mathé (*Sweden*), Julien Mendlewicz (*Belgium*), Hans-Jürgen Möller (*Germany*),  
George Papadimitriou (*Greece*), Philippe H. Robert (*France*), Alan F. Schatzberg (*USA*),  
Dan J. Stein (*South Africa*), Trisha Suppes (*USA*), Eduard Vieta (*Spain*),  
Lars von Knorring (*Sweden*), D. Winkler (*Austria*), Shigeto Yamawaki (*Japan*), Joseph Zohar (*Israel*).

## IMPORTANT ADDRESSES



### Organizing Secretariat

PUBLI CREATIONS - Partner of AIM

74, Bd d'Italie - 98000 Monte-Carlo - Monaco

Ph. +377 97973555 - Fax +377 97973550

E-mail: [ifmad@publiccreations.com](mailto:ifmad@publiccreations.com)

Website: [www.aim-internationalgroup.com/2008/ifmad](http://www.aim-internationalgroup.com/2008/ifmad)

### Congress Venue

Austria Trend Hotel Savoyen Vienna

Rennweg 16, 1030 Vienna, Austria

Ph. +43 (1) 588 00-800 - Fax +43 (1) 588 00-888

Website: [www.austria-trend.at/sav](http://www.austria-trend.at/sav)

# CONTENTS



|                                 |    |
|---------------------------------|----|
| ACKNOWLEDGEMENT                 | 4  |
| WELCOME LETTER - CONGRESS VENUE | 5  |
| PROGRAMME OVERVIEW              | 6  |
| SCIENTIFIC PROGRAMME            | 8  |
| POSTERS                         | 13 |
| SCIENTIFIC INFORMATION          | 20 |
| GENERAL INFORMATION             | 21 |
| ANNOUNCEMENT NEXT FORUM         | 22 |

**FORMS AVAILABLE ON INTERNET:**  
**[www.aim-internationalgroup.com/2008/ifmad](http://www.aim-internationalgroup.com/2008/ifmad)**





## ACKNOWLEDGEMENT

*The Organising Committee  
express their gratitude  
to the following Companies*

**LUNDBECK A/S  
ASTRAZENECA**

for their contribution as Sponsor of Symposia

**PIERRE FABRE MEDICAMENT  
SERVIER**

as Sponsor to the Programme

**WISEPRESS LTD**

for their participation in the exhibition

# WELCOME LETTER



*It is our pleasure to welcome you in Vienna to the annual meeting of the International Forum on Mood and Anxiety Disorders (IFMAD).*

*IFMAD has become an important Forum for the exchange of ideas on the latest developments in psychiatric treatments where international experts can address in an informal atmosphere some of the important topics in the field of mood and anxiety disorders. The meetings are particularly valued for the high quality of the scientific contributions and the opportunity for focused discussion of new data presented in a constructive and productive environment.*

*Attendees at previous meetings have appreciated the very efficient and agreeable formula provided by IFMAD meetings for keeping up to date with current treatment issues. We look forward to renewing old acquaintances at the next meeting and to welcoming an even wider and international audience*

*We are pleased to welcome you in Vienna and have you with us again this year.*

Siegfried Kasper, Chairman

Stuart A. Montgomery, Co-Chairman

# CONGRESS VENUE





# PROGRAMME OVERVIEW

**Wednesday,  
12 November**



**14.30/16.00**  
Will GAD strengthen  
or vanish?

**16.00/16.30**  
*Coffee break*

**16.30/18.00**  
What is new in depression?

**18.00/19.00**  
*Opening reception*

**Thursday,  
13 November**

**09.00/10.30**  
Better treatment outcomes  
from biology to compliance

**10.30/11.00**  
*Coffee break*

**11.00/12.30**  
Quetiapine in the treatment  
of mood disorders

**12.30/13.30**  
*Lunch*

**13.30/15.00**  
Sexual function in depression

**15.00/16.00**  
Debate: "Is bipolar disorder  
over diagnosed?"

**16.00/16.30**  
*Coffee break*

**16.30/18.00**  
Treatment of childhood  
mood disorders

**Friday,  
14 November**

**09.00/10.30**  
The GAP between evidence base  
and experience base in the  
treatment of affective disorder

**10.30/11.00**  
*Coffee break*

**11.00/12.30**  
Oral presentations

**12.30/13.30**  
*Lunch*

**13.30/15.00**  
Obsessive and impulsive  
disorders

**15.00/16.30**  
Dopamine and depression

**16.30/16.45**  
End of meeting





**8<sup>th</sup> INTERNATIONAL  
FORUM ON MOOD  
AND ANXIETY DISORDERS**

**Scientific  
Programme**



### WEDNESDAY, 12 November 2008

#### 14.30 - 16.00 **SO 01 - WILL GAD STRENGTHEN OR VANISH?**

Chairs: **S. Kasper (Austria), A.F. Schatzberg (USA)**

- SO 0101 Is GAD associated with pain and somatoform disorder?  
**Hans Ulrich Wittchen (Germany)**
- SO 0102 Case against merging GAD with major depression  
**Jules Angst (Switzerland)**
- SO 0103 Pharmacological treatment in GAD  
**David Baldwin (UK)**

#### 16.00 - 16.30 **Coffee break**

#### 16.30 - 18.00 **SO 02 - WHAT IS NEW IN DEPRESSION?**

Chairs: **J. Angst (Switzerland), S. Kennedy (Canada)**

- SO 0201 Desvenlafaxine - a new antidepressant  
**Bruno Pitrosky (France)**
- SO 0202 Agomelatine - sleep and depression  
**Sidney Kennedy (Canada)**
- SO 0203 An update on Psychotic and Refractory Depression  
**Alan F. Schatzberg (USA)**

#### 18.00 - 19.00 **Opening reception**





## THURSDAY, 13 November 2008

### 09.00 - 10.30 SO 03 - BETTER TREATMENT OUTCOMES FROM BIOLOGY TO COMPLIANCE

Chair: **S. Kasper (Austria)**

SO 0301 The biology of incomplete response and non-compliance in mood disorders

**Kerry Ressler (USA)**

SO 0302 Why is compliance still an issue and is there anything we can do?

**Fareed Aslam Minhas (Pakistan)**

SO 0303 How to improve treatment outcomes in mood disorders?

**Siegfried Kasper (Austria)**

**Sponsored by an unrestricted educational grant from H. LUNDBECK A/S**

### 10.30 - 11.00 *Coffee break*

### 11.00 - 12.30 SO 04 - QUETIAPINE IN THE TREATMENT OF MOOD DISORDERS

Chair: **S. Montgomery (UK)**

SO 0401 Clinically relevant outcome measures in MDD: focus on the latest Quetiapine XR data

**Stuart Montgomery (UK)**

SO 0402 Quetiapine XR in MDD. Long term efficacy and tolerability

**Koen Demyttenaere (Belgium)**

SO 0403 A translational perspective on Quetiapine. Beyond an atypical

**Svante Nyberg (Sweden)**

**Sponsored by an unrestricted educational grant from ASTRA ZENECA**

### 12.30 - 13.30 *Lunch*



### 13.30 - 15.00 SO 05 - SEXUAL FUNCTION IN DEPRESSION

Chairs: *H.J. Moeller (Germany), J. Sinclair (UK)*

SO 0501 Importance of sexual function in depression and how to assess it  
*Angel Luis Montejo (Spain)*

SO 0502 Antidepressant drugs and sexual function  
*David Baldwin (UK)*

SO 0503 Reversing sexual dysfunction in depression  
*Sidney Kennedy (USA)*

### 15.00 - 16.00 SO 06 - DEBATE:

**"IS BIPOLAR DISORDER OVER-DIAGNOSED?"**

Chair: *S. Montgomery (UK)*

Pro: *Hans Jurgen Möeller (Germany)*

Contra: *Jules Angst (Switzerland)*

### 16.00 - 16.30 *Coffee break*

### 16.30 - 18.00 SO 07 - TREATMENT OF CHILDHOOD MOOD DISORDERS

Chairs: *J.K. Buitelaar (The Netherlands)*  
*A.L. Montejo (Spain)*

SO 0701 Suicide and attempted suicide  
*Zoltán Rihmer (Hungary)*

SO 0702 Depression in children and adolescents  
*Jan K. Buitelaar (The Netherlands)*

SO 0703 Suicide and depression in childhood  
*Julia Sinclair (UK)*



## FRIDAY, 14 November 2008

### 09.00 - 10.30 **SO 08 - THE GAP BETWEEN EVIDENCE BASE AND EXPERIENCE BASE IN THE TREATMENT OF AFFECTIVE DISORDER**

Chairs: **S. Pallanti (Italy), M. Bauer (Germany)**

SO 0801 Minimal design requirement for efficacy and effectiveness  
**Stuart Montgomery (UK)**

SO 0802 Is the antidepressant-placebo difference much greater than previously believed?  
**Zoltán Rihmer (Hungary)**

SO 0803 Practical recommendations for efficacy studies in depression  
**Hans Jurgen Möeller (Germany)**

### 10.30 - 11.00 **Coffee break**

### 11.00 - 12.30 **SO 09 - RECENT DEVELOPMENTS**

Chairs: **S. Pallanti (Italy),  
R. Lanzenberger (Austria)**

SO 0901 SNRI drugs and their place in daily treatment of depression: An exploratory study evaluating milnacipran and venlafaxine in the treatment of adult patients with major depression

**David Gourion (France)**

**Sponsored by unrestricted educational grant from Pierre Fabre**

SO 0902 Imaging genetics: lessons for depression  
**Lukas Pezawas (Austria)**

SO 0903 Seasonal rhythm in Serotonin availability  
**Nicole Praschak-Rieder (Austria)**

### 12.30 - 13.30 **Lunch**



## SCIENTIFIC PROGRAMME

### 13.30 - 15.00 **SO 10 - OBSESSIVE AND IMPULSIVE DISORDERS**

Chairs: **N. Fineberg (UK), G. Papadimitriou (Greece)**

- SO 1001 Is there an impulsive - obsessive spectrum  
**Stefano Pallanti (Italy)**
- SO 1002 The treatment of pathological gambling  
**Peter Berger (Austria)**
- SO 1003 Update on pharmacotherapy of resistant OCD  
**Naomi Fineberg (UK)**

### 15.00 - 16.30 **SO 11 - DOPAMINE AND DEPRESSION**

Chairs: **Z. Rihmer (Hungary), S. Montgomery (UK)**

- SO 1101 Bupropion - a dopamine/noradrenaline antidepressant  
**George Papadimitriou (Greece)**
- SO 1102 Second generation antipsychotics in treatment resistant depression  
**Siegfried Kasper (Austria)**
- SO 1103 Antipsychotics and depression  
**Michael Bauer (Germany)**

### 16.30 - 16.45 **End of meeting**



**P 01.** Relapse prevention and residual symptoms; further analyses of clinical studies with Escitalopram in MDD GAD SAD AND OCD

**P. Bech<sup>1</sup>, K. Overø<sup>2</sup>, S. Lönn<sup>3</sup>**

<sup>1</sup>Psychiatric Center North Sealand, Copenhagen University Hospital,, Hillerød, Denmark, <sup>2</sup>Kgs. Lyngby, Lyngby, Denmark, <sup>3</sup>H. Lundbeck A/S, International Clinical Research, Copenhagen Valby, Denmark

**P 02.** Autonomic regulation and coping style in panic disorder

**A. Bellomo<sup>1</sup>, A. Petito<sup>2</sup>, M. De Rosas<sup>2</sup>, M. Altamura<sup>1</sup>, S. Iuso<sup>2</sup>, M. la Salandra<sup>1</sup>, G. Cibelli<sup>2</sup>, A. Federici<sup>3</sup>**

<sup>1</sup>Department Medical and Occupational Sciences, University of Foggia, Foggia, Italy, <sup>2</sup>Department Biomedical Sciences, University of Foggia, Foggia, Italy, <sup>3</sup>Department Pharmacology and Human Physiology; University of Bari, Bari, Italy

**P 03.** Association between generalized anxiety disorder and somatic symptoms: a Spanish descriptive study

**M. Blanca<sup>1</sup>, S. Mainar<sup>2</sup>, R. Navarro<sup>3</sup>, N. Muro<sup>4</sup>, B. Pascual<sup>4</sup>, L. Garcia<sup>4</sup>**

<sup>1</sup>Department of Psychiatry, Badalona Serveis Assistencials, Badalona (Barcelona), Spain, <sup>2</sup>Directorate of Planning, Badalona Serveis Assistencials, Badalona (Barcelona), Spain, <sup>3</sup>Medical Documentation Service, Hospital Germans Triás i Pujol, Badalona (Barcelona), Spain, <sup>4</sup>Department of Pharmacy, Badalona Serveis Assistencials, Badalona (Barcelona), Spain

**P 04.** Atypical antipsychotic therapy in mood disorders: a cross-sectional assessment of a primary health care database in Spain

**M. Blanca<sup>1</sup>, A. Sicras<sup>2</sup>, R. Navarro<sup>3</sup>, J. Rejas<sup>4</sup>**

<sup>1</sup>Department of Psychiatry, Badalona Serveis Assistencials, Badalona (Barcelona), Spain, <sup>2</sup>Directorate of Planning, Badalona Serveis Assistencials, Badalona (Barcelona), Spain, <sup>3</sup>Medical Documentation Service, Hospital Germans Triás i Pujol, Badalona (Barcelona), Spain, <sup>4</sup>Department of Health Outcomes Research, Medical Unit, Pfizer España, Alcobendas (Madrid), Spain

**P 05.** Minor Mixed Depression in Forensic Psychiatry

**C.V. de Blécourt**

Forensic Psychiatric Center Oldenkotte, The Netherlands

**P 06.** Psychiatric comorbidity, hospitalization and medication use in bipolar children and adolescents with and without rapid cycling

**R. Castilla-Puentes<sup>1,2</sup>**

<sup>1</sup>Department of Psychiatry School of Medicine, University of North Carolina, Chapel Hill, NC, Usa, <sup>2</sup>Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, Usa

**P 07.** Treatment delay and outcome in obsessive-compulsive disorder: a naturalistic study

**B. Dell'Osso , G. Colombini , M. Buoli , A.C. Altamura**

Department of Psychiatry, University of Milan, Fondazione IRCCS Ospedale Policlinico, Mangiagalli e Regina Elena, Milan, Italy



**P 08.** Satisfaction with Medication and Response to Treatment with Escitalopram Compared to Placebo and SNRIs

**K. Demyttenaere<sup>1</sup>, E. Heldbo Reines<sup>2</sup>, S. Larsson Lönn<sup>2</sup>, M. Lader<sup>3</sup>**

<sup>1</sup>Department of Psychiatry, University Hospital Gasthuisberg, Leuven, Belgium, <sup>2</sup>H. Lundbeck A/S, International Clinical Research, Copenhagen Valby, Denmark, <sup>3</sup>Clinical Psychopharmacology, Institute of Psychiatry, King's College London, Denmark Hill, London, United Kingdom

**P 09.** Adolescents psychiatric comorbidity among substance abuse

**J. Djurkovic-Lazic<sup>1</sup>, B. Lazic<sup>2</sup>, D. Djuric<sup>3</sup>**

<sup>1</sup>Institute of Psychophysiological and speech pathology, Beograd, Serbia, <sup>2</sup>General Hospital, Sabac, Serbia, <sup>3</sup>Faculty of Medicine, Kragujevac, Serbia

**P 10.** Double-blind study of the efficacy and tolerability of extended release Quetiapine Fumarate (Quetiapine XR) monotherapy in patients with major depressive disorder (MDD)

**W. Earley<sup>1</sup>, A. McIntyre<sup>2</sup>, G. Wang<sup>3</sup>, S. Raines<sup>1</sup>, H. Eriksson<sup>1</sup>**

<sup>1</sup>AstraZeneca Pharmaceuticals, Wilmington, United Kingdom, <sup>2</sup>Penticton Regional Hospital, Department of Psychiatry, Penticton, British Columbia, Canada, <sup>3</sup>Ankang Hutong, Xicheng District, Beijing, China

**P 11.** Double-blind, randomised study of extended release Quetiapine Fumarate (Quetiapine XR) monotherapy in elderly patients with generalized anxiety disorder (GAD)

**H. Eriksson<sup>1</sup>, I. Mezhebovsky<sup>2</sup>, K. Mägi<sup>3</sup>, F. She<sup>1</sup>, C. Datto<sup>1</sup>**

<sup>1</sup>AstraZeneca Pharmaceuticals, Wilmington, Usa, <sup>2</sup>Cambridge St, Department of Psychiatry, Brighton, Usa, <sup>3</sup>Psychiatric Clinic of the Tartu University Hospital, Tartu, Estonia

**P 12.** Speed of processing in patients who suffer from depression and anxiety

**S. Fernandez Biesa<sup>1</sup>, A. Nieto<sup>2</sup>, J. Barroso<sup>3</sup>, I. Galtier<sup>4</sup>, B. Curbelo<sup>5</sup>**

<sup>1</sup>Canary University Hospital-Department of Psychiatry, Tenerife, Spain, <sup>2</sup>La Laguna University-Department of Neuropsychology, Tenerife, Spain, <sup>3</sup>La Laguna University-Department of Neuropsychology, Tenerife, Spain, <sup>4</sup>La Laguna University-Department of Neuropsychology, Tenerife, Spain, <sup>5</sup>Taco Primary Healthcare Service, Tenerife, Spain

**P 13.** SNRI drugs and their place treatment of depression: an exploratory study evaluating Milnacipran and Venlafaxine in the treatment of adult patients with MDD

**D. Gourion<sup>1</sup>, J.-P. Olié<sup>2</sup>**

<sup>1</sup>Paris, France, <sup>2</sup>Sainte Anne Hospital, Mental Health Service, Paris, France

**P 14.** Leptin modulates orexin-mediated functions at the behavioural and cellular level in mice

**C. Grundschober<sup>1</sup>, F. Delerue<sup>1</sup>, E. Prinssen<sup>1</sup>, J.-L. Moreau<sup>1</sup>, J.G. Wettstein<sup>1</sup>, C. Lopez-Lopez<sup>1</sup>**

<sup>1</sup>CNS Research, F. Hoffmann-La Roche Ltd., Basel, Switzerland



**P 15.** Subtypes of depression in Alzheimer's disease and other dementias.

**M Habeych<sup>1</sup>, R Castilla-Puentes<sup>2,3</sup>**

<sup>1</sup>University of Pittsburgh, Pittsburgh, PA, Usa, <sup>2</sup>University of North Carolina, Chapel Hill, NC, Usa, <sup>3</sup>University of Pennsylvania, Philadelphia, PA, Usa

**P 16.** Functional and structural alterations of Midcingulate Cortex reflect depression vulnerability

**B. Hartinger<sup>1</sup>, M. Nagl<sup>1</sup>, C. Kasess<sup>1,2</sup>, B. Kandler<sup>1</sup>, C. Scharinger<sup>1</sup>, W. Huf<sup>1</sup>, G. Pail<sup>1</sup>, K. Kalcher<sup>1</sup>, S. Russo-Schwarzbaum<sup>1</sup>, A. Erfurth<sup>1</sup>, H. Esterbauer<sup>4</sup>, C. Windischberger<sup>1,2</sup>, S. Kasper<sup>1</sup>, E. Moser<sup>2,3</sup>, L. Pezawas<sup>1</sup>**

<sup>1</sup>Medical University of Vienna, Department of Psychiatry and Psychotherapy, Vienna, Austria, <sup>2</sup>Medical University of Vienna, MR Centre of Excellence, Vienna, Austria, <sup>3</sup>Medical University of Vienna, Center of Biomedical Engineering and Physics, Vienna, Austria, <sup>4</sup>Medical University of Vienna, Clinical Institute of Medical and Chemical Laboratory Diagnostics, Vienna, Austria

**P 17.** E-bibliotherapy: a new minimal contact therapy form

**E. Hasz**

PPKE BTK TO, Piliscsaba, Hungary

**P 18.** Emotion-related bottom-up regulation of frontal cortical memory networks

**W. Huf<sup>1</sup>, A.L. Goldman<sup>2</sup>, G. Pail<sup>1</sup>, S. Kasper<sup>1</sup>, G. Chen<sup>4</sup>, A. Meyer-Lindenberg<sup>2,3</sup>, V.S. Mattay<sup>2</sup>, L. Pezawas<sup>1,2</sup>, D. Weinberger<sup>2</sup>**

<sup>1</sup>Medical University of Vienna, Division of Biological Psychiatry, Vienna, Austria, <sup>2</sup>National Institute of Mental Health - Genes, Cognition and Psychosis Program, Bethesda, MD, Usa, <sup>3</sup>Central Institute of Mental Health, Department of Psychiatry and Psychotherapy, Mannheim, Germany, <sup>4</sup>National Institute of Mental Health - Scientific and Statistical Computing Core, Bethesda, Usa

**P 19.** "Subjective Mania Scale" (SMS). What are the drug effects that bipolar patients really want?

**G. Kaiser<sup>1</sup>, A. Unger<sup>2</sup>, M. Bach<sup>3</sup>, A. Riessland-Seifert<sup>4</sup>, C. Egger<sup>5</sup>, M. Mühlbacher<sup>6</sup>, H. Rittmannsberger<sup>7</sup>, C. Simhandl<sup>8</sup>, J. Wancata<sup>9</sup>**

<sup>1</sup>Medical University of Vienna, Vienna, Austria, <sup>2</sup>Medical University of Vienna, Vienna, Austria, <sup>3</sup>LKH Steyr, Steyr, Austria, <sup>4</sup>Sozialmed. Zentrum Ost, Vienna, Austria, <sup>5</sup>PMU Salzburg, Salzburg, Austria, <sup>6</sup>PMU Salzburg, Salzburg, Austria, <sup>7</sup>Nervenlinik Linz, Linz, Austria, <sup>8</sup>LKH, Neunkirchen, Austria, <sup>9</sup>Medical University of Vienna, Vienna, Austria

**P 20.** Subcortical alterations of brain morphology in healthy and remitted depressed subjects

**K. Kalcher<sup>1</sup>, C. Scharinger<sup>1</sup>, C. Kasess<sup>1,2</sup>, B. Kandler<sup>1</sup>, B. Hartinger<sup>1</sup>, W. Huf<sup>1</sup>, G. Pail<sup>1</sup>, M. Nagl<sup>1</sup>, S. Russo-Schwarzbaum<sup>1</sup>, A. Erfurth<sup>1</sup>, H. Esterbauer<sup>4</sup>, C. Windischberger<sup>1,2</sup>, S. Kasper<sup>1</sup>, E. Moser<sup>2,3</sup>, L. Pezawas<sup>1</sup>**

<sup>1</sup>Medical University of Vienna, Department of Psychiatry and Psychotherapy, Vienna, Austria, <sup>2</sup>Medical University of Vienna, MR Centre of Excellence, Vienna, Austria, <sup>3</sup>Medical University of Vienna, Center of Biomedical Engineering and Physics, Vienna, Austria, <sup>4</sup>Medical University of Vienna, Clinical Institute of Medical and Chemical Laboratory Diagnostics, Vienna, Austria



**P 21.** Effective connectivity as a depression vulnerability marker

**C.H. Kasess<sup>1,2,3</sup>, B. Hartinger<sup>1</sup>, B. Kandler<sup>1</sup>, C. Scharinger<sup>1</sup>, W. Huf<sup>1</sup>, G. Pail<sup>1</sup>, M. Nagl<sup>1</sup>, K. Kalcher<sup>1</sup>, S. Russo-Schwarzbaum<sup>1</sup>, A. Erfurth<sup>1</sup>, H. Esterbauer<sup>4</sup>, C. Windischberger<sup>2,3</sup>, S. Kasper<sup>1</sup>, E. Moser<sup>2,3</sup>, L. Pezawas<sup>1</sup>**

<sup>1</sup>Division of Biological Psychiatry, Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria, <sup>2</sup>MR Centre of Excellence, Medical University of Vienna, Vienna, Austria, <sup>3</sup>Center for Biomedical Engineering and Physics, Medical University of Vienna, Vienna, Austria, <sup>4</sup>Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, Vienna, Austria

**P 22.** Superiority of Escitalopram over Paroxetine in the treatment of Major Depressive Disorder (MDD)

**S. Kasper<sup>1</sup>, D. Baldwin<sup>2</sup>, Jp. Boulenger<sup>3</sup>**

<sup>1</sup>Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria, <sup>2</sup>Clinical Neuroscience Division, University of Southampton, Southampton, United Kingdom, <sup>3</sup>CHU de Montpellier and INSERM U-888, University Department of Adult Psychiatry, Montpellier, France

**P 23.** Efficacy and tolerability of once-daily extended release Quetiapine Fumarate (Quetiapine XR) monotherapy in elderly patients with major depressive disorder (MDD)

**H. Katila<sup>1</sup>, I. Mezhebovsky<sup>2</sup>, A. Mulroy<sup>3</sup>, L. Berggren<sup>4</sup>, C. Datto<sup>5</sup>, H. Eriksson<sup>5</sup>**

<sup>1</sup>Helsinki University Central Hospital, Helsinki, Finland, <sup>2</sup>Cambridge St, Department of Psychiatry, Brighton, Usa, <sup>3</sup>Clinical Trials of Texas Inc., Department of Psychiatry, San Antonio, Usa, <sup>4</sup>AstraZeneca Pharmaceuticals, Södertälje, Sweden, <sup>5</sup>AstraZeneca Pharmaceuticals, Wilmington, Usa

**P 24.** The role of biochemical and immunological markers in antidepressant treatment

**D. Marinescu<sup>1</sup>, I. Marinescu<sup>2</sup>, M. Pirlog<sup>1</sup>**

<sup>1</sup>University of Medicine and Pharmacy of Craiova, Craiova, Romania, <sup>2</sup>Clinic of Psychiatry, Craiova, Romania

**P 25.** Caffeine challenge in patients with panic disorder: baseline differences between panickers and non-panickers

**V. Masdrakis<sup>1</sup>, N. Vaidakis<sup>1</sup>, I. Papakostas<sup>1</sup>, C. Papageorgiou<sup>1</sup>, A. Pehlivanidis<sup>2</sup>, G. Papadimitriou<sup>1</sup>**

<sup>1</sup>Athens University Medical School, <sup>1st</sup> Department of Psychiatry, Eginition Hospital, Athens, Greece, <sup>2</sup>University Medical School, Department of Psychiatry, Eginition Hospital, Athens, Greece

**P 26.** A GPRD-based comparison of second-line antidepressant therapy with escitalopram and venlafaxine

**AG. Wade<sup>1</sup>, D. Milea<sup>2</sup>, N. Despiegel<sup>2</sup>, F. Guelfucci<sup>3</sup>, M. Toumi<sup>4</sup>**

<sup>1</sup>CPS Research, Glasgow, United Kingdom, <sup>2</sup>Lundbeck SAS, Paris, France, <sup>3</sup>Altipharm, Paris, France, <sup>4</sup>Université Lyon I, Lyon, France

**P 27.** Comparison of real-world observed persistence for patients treated with escitalopram and other antidepressants in a french setting: a database study

**K. Kostev<sup>1</sup>, A. Jha<sup>2</sup>, P. Verpillat<sup>3</sup>, D. Milea<sup>3</sup>**

<sup>1</sup>IMS Health, Frankfurt, Germany, <sup>2</sup>IMS Health, London, United Kingdom, <sup>3</sup>H. Lundbeck A/S, Copenhagen, Denmark





**P 28.** Surface-based analysis of cortical thickness in healthy subjects and remitted depressed patients

**M. Nagl<sup>1</sup>, B. Kandler<sup>1</sup>, C. Scharinger<sup>1</sup>, B. Hartinger<sup>1</sup>, C. Kasses<sup>1,2</sup>, W. Huf<sup>1</sup>, G. Pail<sup>1</sup>, K. Kalcher<sup>1</sup>, S. Russo-Schwarzbaum<sup>1</sup>, A. Erfurth<sup>1</sup>, H. Esterbauer<sup>4</sup>, C. Windischberger<sup>1,2</sup>, S. Kasper<sup>1</sup>, E. Moser<sup>2,3</sup>, L. Pezawas<sup>1</sup>**

<sup>1</sup>Medical University of Vienna, Department of Psychiatry and Psychotherapy, Vienna, Austria, <sup>2</sup>Medical University of Vienna, MR Centre of Excellence, Vienna, Austria, <sup>3</sup>Medical University of Vienna, Center of Biomedical Engineering and Physics, Vienna, Austria, <sup>4</sup>Medical University of Vienna, Clinical Institute of Medical and Chemical Laboratory Diagnostics, Vienna, Austria

**P 29.** Penile amputation after trazodone induced priapism

**D. Neu<sup>1</sup>, P. Hoffmann<sup>2</sup>, E.T. Neu<sup>3</sup>**

<sup>1</sup>Brugmann University Hospital, Department of Psychiatry, Brussels, Belgium, <sup>2</sup>Erasmus University Hospital, Department of Urology, Brussels, Belgium, <sup>3</sup>Neu Medical Facility, Department of General Surgery, Wadriil, Germany

**P 30.** Demographic and clinical features and axis I comorbidity in conversion disorder patients in Turkey

**F. Akyuz<sup>1</sup>, S. Erdiman<sup>1</sup>, S. Oflaz Batmaz<sup>2</sup>, S. Bag<sup>1</sup>, C. Karsidag<sup>2</sup>, PG. Gokalp<sup>3</sup>**

<sup>1</sup>Resident of Psychiatry, Bakirköy State Teaching and Research Hospital for Psychiatry and Neurology, Istanbul, Turkey, <sup>2</sup>Specialist in Psychiatry, Bakirköy State Teaching and Research Hospital for Psychiatry and Neurology, Istanbul, Turkey, <sup>3</sup>Associate Professor of Psychiatry, Istanbul, Turkey

**P 31.** Place of Fluvoxamine treatment in prolonged earth-eating (PICA) accompanied with migraine: a case report

**C. Karsidag<sup>1</sup>, S Oflaz<sup>1</sup>, N. Alpay<sup>2</sup>**

<sup>1</sup>Specialist, Bakirkoy State Hospital For Mental Health And Neurological Disorders, Istanbul, Turkey, <sup>2</sup>Chief Of Clinic, Bakirkoy State Hospital For Mental Health And Neurological Disorders, Istanbul, Turkey

**P 32.** A double-blind, placebo-controlled study with acute and continuation phase of quetiapine in adults with bipolar depression (EMBOLDEN II)

**B. Olausson<sup>1</sup>, A.H. Young<sup>2</sup>, W. Chang<sup>3</sup>, B. Paulsson<sup>1</sup>, A. Nordenhem<sup>4</sup>, S.L. Mcelroy<sup>5</sup>**

<sup>1</sup>AstraZeneca R&D, Södertälje, Sweden, <sup>2</sup>University of British Columbia, UBC Institute of Mental Health, Vancouver, Canada, <sup>3</sup>AstraZeneca Pharmaceuticals LP, Wilmington, Usa, <sup>4</sup>Former employee of AstraZeneca R&D, Södertälje, Sweden, <sup>5</sup>University of Cincinnati College of Medicine, Cincinnati, Usa

**P 33.** Efficacy and safety of quetiapine in combination with lithium/divalproex as maintenance treatment for bipolar I disorder (TRIAL 126)

**B. Olausson<sup>1</sup>, E. Vieta<sup>2</sup>, T. Suppes<sup>3</sup>, I. Eggens<sup>1</sup>, I. Persson<sup>1</sup>, B. Björn<sup>1</sup>**

<sup>1</sup>AstraZeneca Pharmaceuticals, Södertälje, Sweden, <sup>2</sup>Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, Barcelona, Spain, <sup>3</sup>Department of Psychiatry and Behavioral Sciences, Stanford Medical Center and V.A. Palo Alto Health Care System, Palo Alto, Usa



**P 34.** Maintenance treatment in bipolar I disorder with quetiapine concomitant with lithium or divalproex: a North American placebo-controlled, randomized trial (TRIAL 127)

**B. Olausson<sup>1</sup>, T. Suppes<sup>2</sup>, E. Vieta<sup>3</sup>, S. Liu<sup>4</sup>, B. Paulsson<sup>1</sup>**

<sup>1</sup>AstraZeneca Pharmaceuticals, Södertälje, Sweden, <sup>2</sup>Department of Psychiatry and Behavioral Sciences, Stanford Medical Center and V.A. Palo Alto Health Care System, Palo Alto, Usa, <sup>3</sup>Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, Barcelona, Spain, <sup>4</sup>AstraZeneca Pharmaceuticals LP, Wilmington, Usa

**P 35.** Placebo-controlled study with acute and continuation phase of quetiapine in adults with bipolar depression (EMBOLDEN I)

**B. Olausson<sup>1</sup>, S.L. Mcelroy<sup>2</sup>, W. Chang<sup>3</sup>, B. Paulsson<sup>1</sup>, A.H. Young<sup>4</sup>**

<sup>1</sup>AstraZeneca R&D, Södertälje, Sweden, <sup>2</sup>University of Cincinnati College of Medicine, Cincinnati, Usa, <sup>3</sup>AstraZeneca Pharmaceuticals LP, Wilmington, Usa, <sup>4</sup>University of British Columbia, UBC Institute of Mental Health, Vancouver, Canada

**P 36.** Quetiapine in the maintenance treatment of bipolar I disorder: combined data from two long-term phase III studies

**B. Olausson<sup>1</sup>, T. Suppes<sup>2</sup>, E. Vieta<sup>3</sup>, S. Liu<sup>4</sup>, H.A. Eriksson<sup>4</sup>, B. Paulsson<sup>1</sup>**

<sup>1</sup>AstraZeneca R&D, Södertälje, Sweden, <sup>2</sup>Department of Psychiatry and Behavioral Sciences, Stanford Medical Center and V.A. Palo Alto Health Care System, Palo Alto, Usa, <sup>3</sup>Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, Barcelona, Spain, <sup>4</sup>AstraZeneca Pharmaceuticals LP, Wilmington, Usa

**P 37.** Quetiapine monotherapy up to 52 weeks in patients with bipolar depression: continuation phase data from the embolden I and II studies

**B. Olausson<sup>1</sup>, A.H. Young<sup>2</sup>, S.L. Mcelroy<sup>3</sup>, W. Chang<sup>4</sup>, A. Nordenhem<sup>5</sup>, B. Paulsson<sup>1</sup>**

<sup>1</sup>AstraZeneca R&D, Södertälje, Sweden, <sup>2</sup>Department of Psychiatry, Institute of Mental Health, The University of British Columbia, Vancouver, Canada, <sup>3</sup>University of Cincinnati College of Medicine, Cincinnati, USA, <sup>4</sup>AstraZeneca Pharmaceuticals LP, Wilmington, Usa, <sup>5</sup>Formerly an employee of AstraZeneca R&D, Södertälje, Sweden

**P 38.** Despair beyond repair?: severity of hopelessness in depressed psychiatric inpatients

**J. Overholser, N. Peak, A. Marquart, L. Fisher**

Case Western Reserve University, Cleveland, Usa

**P 39.** Clinical and neurocognitive changes with Modafinil in obsessive-compulsive disorder: a case report

**A. Padhi<sup>1</sup>, N.A Fineberg<sup>2</sup>, T Johansen<sup>3</sup>, W Dittrich<sup>3</sup>, I.E Smith<sup>4</sup>**

<sup>1</sup>Edinburgh House, Hertfordshire Partnership Foundation Trust, St Albans, United Kingdom, <sup>2</sup>National OCD Treatment Service, Queen Elizabeth II Hospital, Welwyn Garden City, United Kingdom, <sup>3</sup>School of Psychology, University of Hertfordshire, Hatfield, United Kingdom, <sup>4</sup>Papworth Hospital, Respiratory Support and Sleep Centre, Cambridge, United Kingdom



**P 40.** Adjunctive use of Amisulpride in elderly patients with psychotic depression treated with antidepressants

**A. Politis, C. Theleritis, C. Psarros, Cr. Soldatos, Gn. Papadimitriou**

Athens University Medical School, 1<sup>st</sup> Psychiatry Dept., Eginition Hospital, Athens, Greece

**P 41.** Treating depression in a patient with anorexia nervosa using Bupropion

**S. Samolis<sup>1</sup>, G. Sidiropoulos<sup>2</sup>**

<sup>1</sup>Ippokratio General Hospital of Thessaloniki, Department of Psychiatry, Thessaloniki, Greece,

<sup>2</sup>Papanikolaou General Hospital of Thessaloniki, Department of Psychiatry, Thessaloniki, Greece

**P 42.** Atypical depressive symptoms of seasonal affective disorders in women suffering from overweight

**A. Shepenev**

Mental Health Research Institute, Tomsk, Russia

**P 43.** Comparative study of generalized anxiety disorder patients in a Spanish population setting

**A. Sicras<sup>1</sup>, M. Blanca<sup>2</sup>, R. Navarro<sup>3</sup>, N. Muro<sup>4</sup>, L. Garcia<sup>4</sup>, B. Pascual<sup>4</sup>**

<sup>1</sup>Directorate of Planning, Badalona Serveis Assistencials, Badalona (Barcelona), Spain, <sup>2</sup>Department of Psychiatry, Badalona Serveis Assistencials, Badalona (Barcelona), Spain, <sup>3</sup>Medical Documentation Service, Hospital Germans Trias i Pujol, Badalona (Barcelona), Spain, <sup>4</sup>Department of Pharmacy, Badalona Serveis Assistencials, Badalona (Barcelona), Spain

**P 44.** Influence of obesity in co-morbidity and cost among depressive Spanish outpatients

**A. Sicras<sup>1</sup>, M. Blanca<sup>2</sup>, R. Navarro<sup>3</sup>, N. Muro<sup>4</sup>, B. Pascual<sup>4</sup>, L. Garcia<sup>4</sup>**

<sup>1</sup>Directorate of Planning, Badalona Serveis Assistencials, Badalona (Barcelona), Spain, <sup>2</sup>Department of Psychiatry, Badalona Serveis Assistencials, Badalona (Barcelona), Spain, <sup>3</sup>Medical Documentation Service, Hospital Germans Trias i Pujol, Badalona (Barcelona), Spain, <sup>4</sup>Department of Pharmacy, Badalona Serveis Assistencials, Badalona (Barcelona), Spain

**P 45.** Multinational observational study on factors affecting recovery from mania in bipolar disorder in patients treated with atypical antipsychotics: acute phase results

**T. Treuer<sup>1</sup>, F.D. Yang<sup>2</sup>, D. Dikeos<sup>3</sup>, G. Tapia<sup>4</sup>, M. Blinc Pesek<sup>5</sup>, C. Hudita<sup>6</sup>, T. Okasha<sup>7</sup>, R. Nagy<sup>8</sup>, Y. D'Yachkova<sup>9</sup>, G. Harrison<sup>10</sup>**

<sup>1</sup>Eli Lilly and Company, Regional Medical Center, Vienna, Austria, <sup>2</sup>Beijing Hui Long Guan Hospital, Beijing, China, <sup>3</sup>Athens University Medical School on Department of Psychiatry, Athens, Greece, <sup>4</sup>Clinica Tapia, Morelia, Mexico, <sup>5</sup>Psihiatrica ordinacija Rudnik, Ljubljana, Slovenia, <sup>6</sup>Sf. Stelian Center, Bucharest, Romania, <sup>7</sup>Ain Shams University, Cairo, Egypt, <sup>8</sup>Nagykanizsa Municipal Hospital - Psychiatric Department, Nagykanizsa, Hungary, <sup>9</sup>Eli Lilly and Company - GmbH, Vienna, Austria, <sup>10</sup>Eli Lilly and Company - Intercontinental Information Sciences, Sydney, Australia

**P 46.** Once-daily extended release Quetiapine fumarate (Quetiapine XR) monotherapy in Major Depressive Disorder (MDD): analysis in a subgroup of patients with anxious depression

**K. Demyttenaere<sup>1</sup>, M. Thase<sup>2</sup>, W. Earley<sup>3</sup>, M. Astrom<sup>4</sup>, H. Eriksson<sup>3</sup>**

<sup>1</sup>University Hospital Gasthuisberg, Department of Psychiatry, Leuven, BELGIUM, <sup>2</sup>University of Pennsylvania, Department of Psychiatry, Philadelphia, USA, <sup>3</sup>AstraZeneca Pharmaceuticals, Wilmington, USA, <sup>4</sup>AstraZeneca R&D, Södertälje, SWEDEN



## SCIENTIFIC INFORMATION

### Please read carefully

#### **Audio-Visual Facilities:**

Equipment for computerised PowerPoint presentations will be provided during the scientific sessions. Floppy disks and CD-Rom for PowerPoint presentations can be tested prior to presentation in the multimedia slide center.

Floppy disks or CD-Rom must be handed over to the Multimedia Slide Center technicians at least forty minutes before the beginning of the sessions and must be collected directly by the speakers at the end of the session.

It is essential for the smooth running of the sessions that all speakers hand in their PowerPoint presentation in due time.

#### **European Accreditation:**

15 European UEMS (European Union of Medical Specialists) credits have been recognized for this Congress.

#### **Certificate of Attendance:**

A certificate of attendance will be provided, on request, at the registration desk on the last day of the Forum.



# GENERAL INFORMATION



The “8<sup>th</sup> International Forum on Mood and Anxiety Disorders” is held at the Austria Trend Hotel Savoyen Vienna, Rennweg 16, 1030 Vienna, Austria from 12-14 November 2008.

## Admission (Badges):

The participant's name badge will be provided at the registration desk. All participants are requested to wear the badge throughout the Forum. Only badge holders will be admitted to the appropriate sessions, exhibition and social events.

## Coffee breaks and Lunches:

During the Forum sessions, coffee breaks and lunches will be served free of charge to all registered participants, wearing the badge.

## Electricity:

The standard voltage in Austria is 220 V. The Austrian network supply a frequency of 50Hz. Plugs are continental-style two-pins.

## Currency:

The official currency in Austria is the Euro.

## Insurance:

The Forum organizers cannot accept liability for personal injuries sustained, or for loss or damage to property belonging to Forum participants and accompanying persons, either during or as a result of the Forum. Registration does not include insurance. It is strongly recommended that you take an insurance policy of your choice upon Registration to the Forum and booking of your travel. The insurance should be purchased in your country of origin.

## Language:

The official language of the Forum is English. No simultaneous translation will be provided. The language spoken in Austria is German. Most Austrians speak English.

## Mobile phones:

Delegates are kindly requested to switch their mobile phones off during the scientific sessions.

## Secretariat Desk:

The Secretariat desk will open on Wednesday, 12<sup>th</sup> November 2008 and stay open all through the Forum as follow:

- Wednesday, November 12 .....12h00 - 18h00
- Thursday, November 13 .....08h30 - 18h00
- Friday, November 14 .....08h00 - 16h00

## Smoking Policy:

The 8<sup>th</sup> International Forum on Mood and Anxiety Disorders is a non-smoking venue. Forum participants are kindly requested to refrain from smoking in the Forum venue, including the exhibition area and restrooms.

## Tips:

Service is usually included in the prices in bars and restaurants, but tips are welcome.

## Useful Telephone Numbers:

- Ambulance and Emergency Services: ..... **144**
- Emergency Doctor: ..... **141**
- Euro Emergency number: ..... **112**
- Police: ..... **133**
- Fire department: ..... **122**
- Night and weekend dental services: **5 12 20 78**
- Pharmacies open nights and Sunday: ..... **1550**

## Other Useful Numbers

- Vienna International Airport: infoline **+43 7007 22233** (24 hours) [www.viennairport.com](http://www.viennairport.com)
- Taxi: **7007-35910/35905**


# **ANNOUNCEMENT OF NEXT FORUM**

**The 9<sup>th</sup> INTERNATIONAL  
FORUM ON MOOD  
AND ANXIETY DISORDERS**  
will be held in Vienna  
**AUSTRIA**



# Forum Venue

Austria Trend Hotel Savoyen Vienna - Rennweg 16, 1030 Vienna





# Cipralex - the power to tackle depression at its core

Leaving no one behind

Lundbeck



**Cipralex**  
escitalopram

Prescription (Cipralex<sup>®</sup>) tablets containing 5, 10 and 20 mg escitalopram (as escitalopram) are used to treat major depressive disorder and anxiety disorders. Paroxymine tablets are used to treat anxiety disorders with or without agoraphobia, panic disorder and claustrophobia, comorbid depression. Escitalopram tablets (containing 5 mg escitalopram) are used to treat major depressive disorder in the elderly (65 years), in particular in patients and in patients with reduced hepatic function at an initial dose of 5 mg daily. Escitalopram tablets are also used to treat anxiety disorders in patients with severely reduced renal function. Not recommended in children and adolescents (0-17 years). When starting treatment with

escitalopram, the dose should be gradually reduced over a period of one or two weeks. Contraindications: Hypersensitivity to escitalopram. Concurrent treatment with monoamine oxidase (MAO) inhibitors or selective serotonin reuptake inhibitors (SSRI) is contraindicated. Breast-feeding women should not be treated. Precautions: The special warnings and precautions which apply to the class of SSRIs. Drug interactions: Be careful with selective MAO-A, Serotonins (tricyclics, MAO-B inhibitors), Medicinal products lowering the seizure threshold (e.g. anti-epileptics, enzyme inhibitors (e.g. amoxicillin and clindamycin)

may increase the effect of escitalopram). Drugs metabolized by enzyme CYP 2D6 or CYP 3A4. Adverse events: Adverse events most frequent during first or second weeks, comprise the SSRI class adverse events, e.g. nausea, diarrhoea, and constipation. Dosage range: Doses between 100 and 800 mg of escitalopram salts have been taken without any severe symptoms. Consult full prescribing information before prescribing it. Lundbeck 605, Copenhagen, Denmark. Date of preparation: May 2023.